Samuel Sperry

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Siegfried Reich, Paul A. Sprengeler, Gary G. Chiang et al. · Journal of Medicinal Chemistry · 2018 · 177 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Justin T. Ernst, Peggy A. Thompson, Christian Nilewski et al. · Journal of Medicinal Chemistry · 2020 · 145 citations · Full text

Life Sciences, Oncology, Pharmacology +16

Identification of Novel HSP90α/β Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington’s Disease

Justin T. Ernst, Timothy D. Neubert, Michael C. Liu et al. · Journal of Medicinal Chemistry · 2014 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Peggy A. Thompson, Boreth Eam, Nathan P. Young et al. · Molecular Cancer Therapeutics · 2020 · 45 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Kevin R. Webster, Vikas Goel, Ivy N. Hung et al. · Blood · 2015 · 26 citations

Medicine, Oncology, Pharmacology +6